首页分子通1-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-3-{3-isopropyl-1'-[2-(4-methylpiperazin-1-yl)ethyl]-1'H-[1,4']bipyrazolyl-5-yl}urea formate salt
1-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-3-{3-isopropyl-1'-[2-(4-methylpiperazin-1-yl)ethyl]-1'H-[1,4']bipyrazolyl-5-yl}urea formate salt
1-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-3-{3-isopropyl-1'-[2-(4-methylpiperazin-1-yl)ethyl]-1'H-[1,4']bipyrazolyl-5-yl}urea formate salt
Compounds of formula (I) described herein are p38 MAPK inhibitors and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.